TEER

MITRACLIP™ Transcatheter Edge-to-Edge Repair

MitraClip™ is the first minimally invasive TEER* therapy that delivers a life-changing treatment option for select patients with primary or secondary mitral regurgitation who would otherwise go untreated.1,2 MitraClip is the standard of care in TMVr built on the only proven mitral valve therapy with over 18 years of experience, an extensive body of clinical evidence, and more than 150K patients treated worldwide.3

*TEER is also referred to TMVr (Transcatheter Mitral Valve Repair)

Built to Repair. Proven to Restore.

MitraClip delivers uncompromising performance in TEER and sets the standard in clinical outcomes. With each generation of MitraClip, Abbott remains at the forefront of therapeutic expertise, partnering with heart teams to help select patients with MR reclaim their lives.

A better quality of life is possible for your patients with MR


MitraClip™ transcatheter edge-to-edge repair (TEER) is a minimally invasive treatment option for select patients with:

  • Significant Primary MR patients who are at a prohibitive surgical risk
  • Significant secondary MR patients who remain symptomatic despite maximally tolerated GDMT

FIND A MITRACLIP CENTER

 


The Catalyst for a Significant Evolution in MR Guideline

Transcatheter edge-to-edge repair (TEER) therapy is now recommended by both the 2022 AHA/ACC/HFSA Guideline4 and the 2020 ACC/AHA Guideline5 for select primary and secondary* MR patients. Determining the severity of MR is an important factor in the management of the condition. The guidelines4,5 support aggressive monitoring and early action, with the goal of preventing complications due to LV volume overload.4

MitraClip is the only US-approved TEER, serving as the foundation for TEER recommendations for both primary MR and secondary MR.4
 


*Severely symptomatic SMR patients despite optimal GDMT.
 


Severe MR is vastly undertreated

  • Surgical intervention not offered or denied


    49% of patients with symptomatic severe MR were not operated due to age, co-morbidities, or impaired LV.5 If left untreated, MR initiates a cascade of events leading to death, with 1-year mortality up to 57%6

IDENTIFYING PATIENTS FOR MITRACLIP THERAPY


Transcatheter Mitral Valve Repair Patient Screening
Fact Sheet (For Primary MR)

 

DOWNLOAD NOW


MitraClip Transthoracic Echo (TTE)
Screening Guide

 

DOWNLOAD NOW

Tailored. Optimized. Proven.
MitraClip™ G4

MitraClip TEER system’s dedicated design for the mitral anatomy optimizes navigation for consistent clinical results. Its proven performance and tailored treatment options allow it to treat the broadest range of mitral anatomies.

  • Broad Range of Sizes for Tailored Treatment9,10

    MitraClip G4 offers 4 Clip sizes to help tailor repair based on patient mitral valve anatomy.

    • G4 NT is the original MitraClip NT/NTR Clip size
    • G4 XT is the equivalent of XTR, with Clip arms that are 3 mm longer than G4 NT and allow for easier grasping due to better reach**
       

    The G4 NTW and XTW clips have a 50% wider grasping area than the NT and XT clips respectively. They are designed to reduce MR with the implantation of a single clip.**

  • Treat more patients with more options8,9

    MitraClip successfully treats a broad range of valve anatomies in real world use9,10

    Nearly 1 in 5 patients treated have valve anatomies considered complex9

    Valve anatomies include: presence of severely degenerative leaflets, wide flail gaps or widths, calcified landing zone, wide jet, primary jet outside of A2/P2, and more.9


    Long arm clip use was associated with improved MR reduction for severe baseline MR, smaller annular dimensions, larger prolapse gaps and complex mitral valve anatomy in primary MR.

    – Cardiac Surgeon with over 10 years of experience with MitraClip*
     

    *The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual’s experience and might not be representative of others.

    Clip selection recommendations based on mitral valve anatomy1,8,9

    CLIP SELECTION CONSIDERATIONS

    FAVORS
    G4 NTW
    FAVORS
    G4 NT
    FAVORS
    G4 XTW
    FAVORS
    G4 XT
    Leaflet Length < 9mm++  
    Leaflet Length ≥ 9mm  ++
    Broad Jet+ + 
    Smaller Valve +  
    Larger Valve+ ++

    MitraClip G4 Clip selection recommendations are based on the clinical experience of physicians. The EXPAND G4 observational study evaluates adherence to Clip size selection recommendations and their associated outcomes.

  • More options to confirm and optimize leaflet grasping with Controlled Gripper Actuation (CGA)1,3

    Controlled Gripper Actuation (CGA) provides the option to grasp leaflets simultaneously or independently, enabling the ability to confirm and optimize leaflet grasp.

    NEW GRIPPER
    LEVERS

    SIMULTANEOUS
    GRASPING

    INDEPENDENT
    GRASPING

  • Predictable procedure experience8,**

    The innovative Clip Delivery System is a highly maneuverable delivery catheter that is used to implant the MitraClip via a Steerable Guide Catheter.

    Precision and stability from delivery system specifically designed for the mitral valve**
     

  • Increased procedural efficiency1,10

    GREATER PROPORTION
    OF PATIENTS TREATED
    WITH 1 CLIP8

    1 CLIP IMPLANTED IN
    58% OF CASES 8

     

    26% REDUCTION
    IN PROCEDURAL
    TIME8

    34 MIN. AVERAGE
    DEVICE TIME8



    “IN OUR INSTITUTE, WE HAVE NOW REDUCED DEVICE TIME TO ~20 MIN.”

    Echocardiographer with 6 years of MitraClip experience, commenting on MitraClip G4*




     

    Simplified procedural steps1

    • 40% reduction in system preparation steps
    • Simplified system deployment with minimal number of steps
       

LEARN MORE ABOUT MITRACLIP G4 FEATURES BY VISITING MITRACLIP.COM

Learn more

Webinars

Watch our webinars to learn more about how MitraClip can benefit physicians and help patients live longer, fuller lives.

VIEW All Webinars

 MAT-2010220 v4.0 | Item approved for U.S. use only.

Copyright © 2023 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2004021 v15.0  |   Item approved for U.S. use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.